Certificate Programs Can Help Scientists Transition to Alternative Careers
.jpg)
By now, I think that most BioJobBlog readers understand that the job market for life scientists is lousy and that it isn’t likely to improve anytime soon. I know that many of you have spent close to 10 years training for a shot at an R&D job but the reality is that everybody needs to work to put food on the table—whether or not you find a job in your chosen profession. To that end, now may be a good time for those of you who are finding it difficult to land a job to consider one more year of training to get a certificate in a field that keeps you in science but not in R&D.
I came across interesting post today at the Resume Bear blog that discussed 10 certificate programs that can help people transition to new careers to find jobs. Interestingly, four of the programs are good fits for life scientists who are willing modify their careers to be gainfully employed. They are:
Clinical Trials Design and Management
“Pharmaceutical drug and medical device development is one of the premier industries of the 21st century, and the success of this vital industry depends upon the complex process of studying new products to verify their effectiveness and safety.”
Regulatory Affairs
“Professionals are needed to guide drug development and medical device companies through FDA imposed regulation issues pertinent to the pharmaceutical and biological industry.”
Project Management
“As project cycles get shorter – and budgets get leaner – project managers are vital to the success of organizations today.”
Copyediting
“Bridging the gap between writers and publishers – especially technical and nonfiction copyediting – is one of today’s most marketable skills for both full-time and freelance work.”
Another one that was not on the list biotechnology certificate programs in which students learn about product development, regulatory affairs and best business practices in the life sciences industry.
Not surprisingly, many certificate programs are offered at local community colleges and frequently online. For regulatory affairs training you might try the Drug Information Association and Regulatory Affairs Professionals Society. The Project Management Institute offers training in project management and the Editorial Freelancers Association offers its members courses in copyediting. Mercer County College in West Windsor NJ in association with a local clinical research organization developed a “hands-on” certificate program in clinical trials design and management.
In my opinion, certificate programs are worth checking out. They are designed for working professionals (courses are typically given in the evenings and weekends); usually only take 12 months to complete (what is one more year in the scheme of things) and improves the likelihood of finding a job because you now have a marketable skill set! It certainly beats collecting unemployment or sleeping in your old bed at your parent’s home—or not?
Hat tip to Resume Bear
Until next time...
.gif)
Over the past three years, more than
Last month, while I was presenting my seminar “Interviewing Insights and Tips: Winning That Next Job” at the Experimental Biology Meeting in New Orleans, LA, I realized that I hadn’t covered what to wear to a job interview. Until the meeting, I didn’t think I had to mention— that while interviewing men—must wear suits (and appropriately-colored, professional-looking shoes) and women should wear suits with pants (or a skirt with an appropriate length) and shoes with reasonable heels (usually less than 3 inches). I saw more cleavage, bare thighs and high heels, not to mention men with atrocious footwear choices at the meeting than I care to admit. Not that I am a prude or complaining about the cleavage, thighs or high heels that I observed—what red-blooded American male would? That said, it is vitally important to remember that there are professional dress codes that everyone is expected to adhere to while on the job or at national, regional or local professional meetings.
The National Institutes of Health (NIH) announced on Wednesday that it was creating a new program aimed at “finding treatments for some of the 6,800 rare diseases that collectively affect about 25 million Americans.” 
Johnson & Johnson (JNJ) is trying to regain sole marketing rights to Remicade, its lucrative anti-TNF treatment for arthritis and psoriasis, because Schering Plough (SGP)—which has most of the marketing rights to the drug outside of the US—is being acquired by Merck. JNJ is seeking arbitration to determine whether or not Centocor, its subsidiary that manufactures Remicade and Simponi, can terminate a marketing agreement for the two drugs—based on terms stipulated in the original contract —if there is a “change of control” at SGP.
Medtronics, the world's largest medical-device company, .jpg)
The Biotechnology Industry Organization (BIO) kicked off its annual meeting in Atlanta, Georgia today and shortly thereafter, issued a 
The New York Times reported today that for the first time, Internet users are spending more time on social networking and video sites than on e-mail. According to a report by Nielsen, there was a 1,905 percentage change in the time that users spent viewing online video and an 883 percentage increase in social networking use from February 2003 to 2009.
Pfizer, the world’s largest drug maker, announced on Thursday that it is unveiling a new program that will let people who have lost their jobs and health insurance to keep taking Pfizer medications — for free, and for up to a year. The company will provide more than 70 of its prescription drugs ranging from Viagra to Lipitor at no costs to unemployed and uninsured Americans who lost their jobs since Jan. 1 and have been taking Pfizer drugs for me than three months. It is not clear how much Pfizer will spend on the program and whether or not costs will be capped.
A team of scientists from the UK report in this week’s edition of Nature that they were able to induce the formation of ribonucleotides using ribose, phosphate and the bases adenine, uracil, guanine and cytosine and environmental conditions that may have been present in the early history of the Earth. This had been a fundamental but elusive step in the early evolution of life on Earth. (1).jpg)
There has been no shortage of conversation lately about current problems facing the pharmaceutical and biotechnology industries. These industries are faced with the effects of the global recession because of a dangerous combination of falling revenues and spiraling costs. Life sciences company executives are looking for ways to cut production costs and cope with the current decline in drug sales.
As we all know, the H1NI pandemic has been raging on for close too 10 ten days now. Curiously, “Fear & The Flu: The New Age of Pandemics” is the title this week’s cover story in Newsweek magazine. From an informational standpoint point, “this may be too little, too late”—as the old saying goes. While the Internet has been around for over twenty years now, government agencies, most notably the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) continue to rely almost exclusively on old media to communicate with the American public during infectious disease outbreaks. Apparently, the administrators who run these government agencies haven’t been listening closely enough to President Obama’s assertion that “we live in the digital age.”.gif)
A quick perusal of the media coverage of the swine flu outbreak of 2009 would lead many to conclude that this outbreak has the potential to rival or surpass the 1918 flu pandemic—widely regarded as the worst influenza outbreak in history. While the emergence of a new H1N1 swine flu variant is significant note worthy— and has possible public health implications— the unrelenting, often scientifically-inaccurate media coverage did little to quell the fear and anxiety of many Americans. Once again, the media—rather than physicians, public health officials and influenza experts—“got out in front of the story” and managed to create enough panic, fear and anxiety, the likes of which haven't been seen since the 2003 SARS pandemic. It wasn't until last Friday, when the Wall Street Journal published an interview with Dr. Peter Palese—a leading scientific expert on influenza A infections— did a clearer picture emerge about the severity and public health implications of the current swine flu pandemic..jpg)
Do you lie awake a night overwhelmed by the possibility of another infectious disease outbreak? Well, if you want to get a good night’s sleep, I highly recommend that you take a look at a brief history of American epidemics that was published in this past Sunday’s New York Times. According to the .jpg)
One day after the US Food and Drug Administration (FDA) approved Dysport, a new product that will compete with Botox, the 
Vincent Racaniello, an intrepid virologist and 